Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Stefania Redana"'
Autor:
Rossella Martinello, Giuseppe Viale, Franco Nolè, Stefania Redana, Massimo Aglietta, Filippo Montemurro, Laura Adamoli, Valentina Rossi, Gaetano Aurilio, Elena Verri, Anna Sapino
Publikováno v:
The Breast. 23:44-49
Background Five to 10% of women with newly diagnosed breast cancer have synchronous metastases ( de novo stage IV). A further 20% will develop metastases during follow-up (recurring stage IV). We compared the clinical outcomes of women with HER2-posi
Autor:
Stefania Redana
Publikováno v:
Breast Cancer Survivorship ISBN: 9783319418568
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d81b7d479315ae1fbe7e46a5383130c1
https://doi.org/10.1007/978-3-319-41858-2_6
https://doi.org/10.1007/978-3-319-41858-2_6
Autor:
Riccardo Ponzone, Daniele Regge, Stefania Redana, Veronica Deantoni, Filippo Montemurro, Massimo Aglietta, Laura Martincich, Franziska Kubatzki, Ilaria Bertotto, Ivana Sarotto, Valentina Rossi, Michele Liotti
Publikováno v:
European Radiology. 22:1519-1528
We evaluated whether the apparent diffusion coefficient (ADC) provided by diffusion-weighted imaging (DWI) varies according to biological features in breast cancer.DWI was performed in 190 patients undergoing dynamic contrast-enhanced magnetic resona
Autor:
Furio Maggiorotto, Riccardo Ponzone, Cont N Tomasi, Massimo Aglietta, Filippo Montemurro, Ivana Sarotto, Stefania Redana, Valentina A. Rossi
Publikováno v:
Cancer Research. 71:P2-12
Purpose: We sought to evaluate whether moderate HER2 immunohistochemical (IHC) expression (2+ and no HER2/amplification) identifies early breast cancer (EBC) with a distinct prognostic profile. Methods: A total of 1295 women (median age 58, range 22
Autor:
M Racca, Stefania Redana, T Varetto, G. Zago, L Evangelista, Filippo Montemurro, Massimo Aglietta, Carolis V De
Publikováno v:
Cancer Research. 71:P1-18
Background: a small percentage of breast cancer (BC) patients (pts) will develop oligo-metastatic disease (OMD), often with a solitary lesion (SL). Growing evidences suggest a survival benefit for pts who undergo local treatment for SL. However, 18-f
Autor:
Giuseppe Viale, Giorgio Valabrega, Aron Goldhirsch, Valentina Rossi, Stefania Redana, Laura Adamoli, Franco Nolè, Rossella Martinello, Maria Cossu Rocca, Elena Verri, Anna Sapino, Filippo Montemurro, Massimo Aglietta
Publikováno v:
Cancer. 118:17-26
BACKGROUND: The relationship between quantitative immunohistochemical hormone receptor expression and response to the combination of trastuzumab with chemotherapy in HER2-positive advanced breast cancer is currently unknown. METHODS: Estrogen recepto
Autor:
Massimo Aglietta, Andrea Milani, Stefania Redana, Elena Geuna, Valentina Rossi, Giorgio Valabrega, Filippo Montemurro
Publikováno v:
Therapy. 8:161-177
Trastuzumab is a monoclonal antibody directed against the product of the HER2/neu oncogene. The HER2 protein is overexpressed in approximately 20% of human breast cancers and is associated with adverse prognosis. Randomized studies in patients with H
Autor:
Rossella Martinello, Giorgio Valabrega, M. Cossu Rocca, A. Goldhirsch, Franco Nolè, Laura Adamoli, Massimo Aglietta, Valentina A. Rossi, Stefania Redana, Elena Verri, Anna Sapino, G. Viale, Filippo Montemurro
Publikováno v:
Cancer Research. 70:PD10-07
Background: Hormone receptors (HR) and the human epidermal growth factor receptor 2 (HER2) are key biological factors in breast cancer. Gene expression profile studies indicate that HER2-positive/HR-positive and HER2-positive/HR-negative tumors fall
Autor:
Gianluigi Lunardi, Gianfranco Filippelli, Stefania Gori, Fotios Loupakis, Francesca Coati, Antonio Rossi, Elena Collovà, Libero Ciuffreda, A. L. Gentile, Gaetano Aurilio, Valter Torri, Vittorio Gebbia, Francesco Atzori, Gabriele Luppi, Stefania Redana, Placido Amadio, Giuseppe Luigi Banna, Ilaria Marcon, Giancarlo Pruneri, Laura Orlando, Francesca Di Fabio, Lucia Del Mastro, Franco Nolè, Nicla La Verde
Publikováno v:
Tumori. 102(1)
Aim To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods A 17-item anonymous questionnaire including 7 general and 10 invest
Autor:
Antonio Durando, M. E. Jacomuzzi, Giorgio Valabrega, Stefania Redana, Guido Vietti-Ramus, Marco Venturini, Massimo Aglietta, S. Danese, Michela Donadio, Matteo Clavarezza, Filippo Montemurro
Publikováno v:
The Oncologist. 11:318-324
We sought to describe patterns of treatment and clinical outcome in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy. One hundred eighty-four consecutive HER2-positive advanced breast cancer patients receive